Insulin pen from Ypsomed to be launched in Germany

Burgdorf, (PresseBox) - B. Braun, one of the world's leading health care providers, will unveil the Omnifill® reusable insulin pen at the conference of the German Diabetes Association (Deutsche Diabetes-Gesellschaft - DDG), to be held in Berlin on 11 and 12 November 2011. This insulin pen uses the cutting-edge ServoPen® platform, which was developed by Ypsomed, and which has won the internationally renowned 'red dot design award'.

B. Braun is to distribute the reusable insulin pen developed by the Burgdorf-based diabetes specialist together with its human insulins, which enjoy an established market presence. The major German corporate group has been active in the German diabetes market for many years.

The ServoPen® impresses with its quality workmanship and its high level of user-friendliness thanks to its semi-automatic mode of operation. These characteristics played an important part in B. Braun's decision to opt for the Swiss-manufactured insulin pen.

'Ypsomed is proud to be able to produce the Omnifill® pen on behalf of B. Braun', confirms Simon Michel, member of the executive management of the Ypsomed Group, and adds: 'This quality product will allow B. Braun to meet the highest requirements in terms of patient comfort and user-friendliness.'

Germany is Europe's largest insulin market with a high rate of growth. Of all insulin dependent diabetics, 95% use insulin pens. Currently, approximately six million people in Germany are diagnosed with diabetes mellitus. Including undetected cases, the total number of diabetics is estimated to be ten million. Experts predict that the number of peo-ple suffering from diabetes will double over the next ten years.

Ypsomed AG

The Ypsomed Group is a leading independent developer and manufacturer of injection systems for self-medication, and a well-known diabetes specialist with more than 25 years of experience; it emerged in 2003 from the Disetronic Group, and provides insulin pumps, injection systems and pen needles for diabetes, growth hormone and infertility treatments, as well as for other therapeutic purposes. Ypsomed is an innovation and technology leader with an exten-sive patent portfolio, and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. Ypsomed has established itself as a leading provider of branded, co-branded and OEM products in the retail and business-to-business segments. As a long-standing partner of renowned pharmaceutical and biotech companies, Ypsomed has a particularly strong commitment to advances in patient care. Under the mylife(TM) Diabetescare brand, Ypsomed provides patients with the products it manufactures or distributes. The Ypsomed Group has its headquarters in Burgdorf, Switzerland. It has several manufacturing sites in Switzerland, as well as leading independent diabetes product sales companies throughout Europe. The Ypsomed Group employs approximately 1,150 employees.

Press releases you might also be interested in

Weitere Informationen zum Thema "Medical Technology":

Diagnose mit der Intelligenz des Bauchgefühls

Ein Sound-Er­ken­nungs­sys­tem ana­ly­siert tech­ni­sche Pro­b­le­me bei Ma­schi­nen auf der Grund­la­ge von Be­triebs­ge­räu­schen und löst Alarm aus.

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.